An update from GlucoTrack ( (GCTK) ) is now available.
On April 3, 2025, Glucotrack announced a strategic agreement with OneTwo Analytics AB to enhance the analysis of clinical study data from its Continuous Blood Glucose Monitor (CBGM) using AI-driven analytics. This collaboration aims to improve insights into the CBGM’s performance and clinical value, potentially revolutionizing diabetes management by providing a more convenient and less intrusive glucose monitoring solution. The partnership is expected to deliver a comprehensive ecosystem combining blood glucose insights, risk stratification data, and patient engagement tools, thereby improving care for millions of people with diabetes.
More about GlucoTrack
Glucotrack, Inc. is a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing a long-term implantable continuous blood glucose monitoring system, which provides real-time readings directly from blood without the lag time associated with traditional interstitial glucose measurements.
YTD Price Performance: -97.32%
Average Trading Volume: 6,638,641
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.76M
Learn more about GCTK stock on TipRanks’ Stock Analysis page.